A Randomized, Open-label, Comparative, Multicenter, Phase II Study of the Efficacy and Safety of REGorafenib Versus Tamoxifen in Patients With Platinum-sensitive OVARian Carcinoma and Isolated Biological Progression
Phase of Trial: Phase II
Latest Information Update: 22 Jun 2018
At a glance
- Drugs Regorafenib (Primary) ; Tamoxifen
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Acronyms REGOVAR
- 23 Aug 2017 Planned End Date changed from 1 May 2020 to 1 May 2022.
- 23 Aug 2017 Planned primary completion date changed from 1 Jun 2016 to 1 Jun 2018.
- 05 Apr 2016 Planned primary completion date changed from 1 Apr 2016 to 1 Jun 2016.